Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

Axsome Therapeutics

Kodiak Sciences Inc

These stocks have soared 935% or more this year. Can they keep the momentum going?

3 Best Biotech Stocks of 2019: Are They Buys Now?

Here's why these drugmaker stocks are the year's top performers.

3 Biotech Stocks That Crushed It in 2019

CAMBRIDGE, Mass., Dec.  13, 2019  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $34.50 per share, which includes 975,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The total gross proceeds of the offering were $257.9 million, before deducting underwriting discounts and commissions and expenses payable by Constellation. All of the shares in the offering are being sold by Constellation.

Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Dec.  10, 2019  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $34.50 per share, for total gross proceeds of $224.3 million, before deducting underwriting discounts and commissions and expenses payable by Constellation. All of the shares in the offering are being sold by Constellation. In addition, Constellation has granted the underwriters a 30-day option to purchase up to 975,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on December 13, 2019, subject to customary closing conditions.

Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock (CNST)

CAMBRIDGE, Mass., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has commenced an underwritten public offering of 4.75 million shares of its common stock. All of the shares are being offered by Constellation. In addition, Constellation expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

Constellation Pharmaceuticals - Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update of preliminary data from the MANIFEST clinical trial in oral and poster presentations at the annual meeting of the American Society of Hematology (ASH) in Orlando.

Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

Constellation Pharmaceuticals had $89.1 million in cash as of September 30, 2019, with enough funds to operate into the first half of 2021.

Constellation Solidifies Epigenetics Platform With Latest Positive Myelofibrosis Data

Ares Commercial Real Estate

Digital Turbine

Cannae Hlds

California Resources

Carrizo Oil & Gas

Signet Jewelers

Southwestern Energy

These are the small cap stocks with the best value, fastest growth, and most momentum for November.

Top Small Cap Stocks for November 2019

Enjoying a blistering run within the last two months, CNST stock has quickly attracted eyeballs. But with such strong momentum, investors shouldn’t lose sight of the tough fundamental picture for pharmaceutical companies.

CNST Stock Is Particularly Risky After Its Recent Run

DaVita

Boingo Wireless

Why Boingo Wireless, DaVita, and Constellation Pharmaceuticals Jumped Today

Shares of Constellation Pharmaceuticals Inc.  jumped 95% after the biopharmaceutical company reported promising data from a mid-stage clinical trial for myelofibrosis.

Constellation shares soar 95% after promising data from rare disease trial

Does Constellation Pharmaceuticals, Inc. (CNST) have what it takes to be a top stock pick for momentum investors?

Here's Why Momentum Investors Will Love Constellation Pharmaceuticals, Inc. (CNST)

As of late, it has definitely been a great time to be an investor Constellation Pharmaceuticals.

Will Constellation Pharmaceuticals Continue to Surge Higher?

CAMBRIDGE, Mass., Oct.  10, 2019  (GLOBE NEWSWIRE) --  Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will present updates of clinical data from the MANIFEST clinical trial of CPI-0610 in oral and poster presentations at the American Society of Hematology (ASH) annual meeting on December 9. Two abstracts reflecting MANIFEST data have been accepted by ASH and will be published on November 6. Updated data will be presented at the meeting.

Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH

Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Constellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session

CAMBRIDGE, Mass., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has entered into a securities purchase agreement with a group of institutional investors for the private placement of $65 million of shares of its common stock. The transaction is expected to close on or about October 3, 2019, subject to the satisfaction of customary closing conditions. The private placement is being led by Venrock Healthcare Capital Partners and includes Bain Capital Life Sciences and affiliates of The Column Group.

Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors

CAMBRIDGE, Mass., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the Cantor Global Healthcare Conference in New York at 12:35 PM EDT on Friday, October 4.  A live audio webcast of this presentation and an archive for replay will be available on the Investor Relations section of Constellation’s website at  http://ir.constellationpharma.com/events   -   and   presentations/events  .  The audio webcast replay will be available for 90 days following the live presentation.

Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference

Potential best-in-class EZH2 inhibitor focused on targeted patient segments was identified using Constellation’s epigenetics platform Potential best-in-class EZH2 inhibitor focused on targeted patient segments was identified using Constellation’s epigenetics platform

Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise

CAMBRIDGE, Mass., Aug.  21, 2019  (GLOBE NEWSWIRE) --  Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two investor conferences on September 5.  Jigar Raythatha, CEO, will meet with investors at the Citi 14th Annual Biotech Conference at the Four Seasons Hotel in Boston.  Emma Reeve, CFO, will present at the Baird Global Healthcare Conference at the InterContinental Hotel in New York at 11:25 am EDT.  A live audio webcast of Ms. Reeve’s presentation and an archive for replay will be available on the Investor Relations section of Constellation’s website at  http://ir.constellationpharma.com/events-and-presentations/events .  The audio webcast replay will be available for 90 days following the live presentation.

News for Constellation Pharmaceuticals Inc Stock (CNST)